Recombinant Human FGFR1a (IIIc) Fc (Carrier-free)
| Cat No. | Size | Price | Quantity | |
|---|---|---|---|---|
| 21-7104-U010 | 10 µg | $69.00 | ||
| 21-7104-U050 | 50 µg | $169.00 | ||
| 21-7104-U100 | 100 µg | $280.00 | ||
| 21-7104-U500 | 500 µg | $859.00 |
Lead time: 2-3 business days
Technical Data Sheet
Request Custom/BulkDescription
The Fibroblast Growth Factor Receptor (FGFR) family is made up of four known closely related receptor tyrosine kinases, FGFR1 through 4. For FGFR1 through 3, alternative splicing results in numerous variants. One common splicing event results in the extracellular domain having all 3 immunoglobulin-like domains (alpha isoform) or only the II and III Ig domains (beta isoform). Additional variation in the IgIII domain allows for expression as IIIb or IIIc, again due to alternative splicing. Ligand binding results in dimerization and autophosphorylation of specific tyrosine residues. Variants may exhibit different ligand binding properties. FGFR1 predominantly binds the FGF-acidic and FGF-basic proteins.
The Fibroblast Growth Factor Receptor (FGFR) family is made up of four known closely related receptor tyrosine kinases, FGFR1 through 4. For FGFR1 through 3, alternative splicing results in numerous variants. One common splicing event results in the extracellular domain having all 3 immunoglobulin-like domains (alpha isoform) or only the II and III Ig domains (beta isoform). Additional variation in the IgIII domain allows for expression as IIIb or IIIc, again due to alternative splicing. Ligand binding results in dimerization and autophosphorylation of specific tyrosine residues. Variants may exhibit different ligand binding properties. FGFR1 predominantly binds the FGF-acidic and FGF-basic proteins.
Hide
Product Details
| Name | Recombinant Human FGFR1a (IIIc) Fc (Carrier-free) |
|---|---|
| Cat. No. | 21-7104 |
| Alternative Names | Fibroblast Growth Factor Receptor 1 alpha, BFGFR, CEK, FLG, HH2, OGD, FLT2, KAL2, CD331, FGFBR, FLT-2, HBGFR, N-SAM, FGFR-1, HRTFDS, bFGF-R-1 |
| Amino Acid Sequence | (Monomer) RPSPTLPEQA QPWGAPVEVE SFLVHPGDLL QLRCRLRDDV QSINWLRDGV QLAESNRTRI TGEEVEVQDS VPADSGLYAC VTSSPSGSDT TYFSVNVSDA LPSSEDDDDD DDSSSEEKET DNTKPNPVAP YWTSPEKMEK KLHAVPAAKT VKFKCPSSGT PNPTLRWLKN SKEFKPDHRI GGYKVRYATW SIIMDSVVPS DKGNYTCIVE NEYGSINHTY QL |
| Authenticity | Verified by N-terminal and Mass Spectrometry analyses (when applicable). |
| Bioactivity | Assay#1: The expected ED50, determined by the dose-dependent stimulation of thymidine uptake by BaF3 cells expressing FGF receptors, is ≤ 0.5 ng/ml corresponding to a specific activity of ≥ 2 x 106 units/mg. Assay #2: The expected ED |
| Endotoxin Level | Endotoxin level is <0.1 ng/μg of protein (<1 EU/μg). |
| Molecular Mass | Recombinant Human FGFR1a (IIIc) migrates between ≥ ≥ ≥ 100-110 kDa on SDS-PAGE gel under reducing conditions. It contains 586 amino acids and is a 65.2 kDa protein. |
| Protein Content | Verified by UV Spectroscopy and/or SDS-PAGE gel. |
| Purity (%) | 95 |
| Source | CHO cells |
| Reactivity | Human |
| Research Areas | Angiogenesis & Cardiovascular, Cancer, Differentiation,? FGF Superfamily, Inflammation, Neurobiology, Stem Cells, Wound Healing |
| Reconstitution | See Certificate of Analysis (COA) for lot specific reconstitution information. |
| Application | Bioassay |
Application Key:
FC = Flow Cytometry; FA = Functional Assays; ELISA = Enzyme-Linked Immunosorbent Assay; ICC = Immunocytochemistry; IF = Immunofluorescence Microscopy; IHC = Immunohistochemistry; IHC-F = Immunohistochemistry, Frozen Tissue; IHC-P = Immunohistochemistry, Paraffin-Embedded Tissue; IP = Immunoprecipitation; WB = Western Blot; EM = Electron Microscopy
*Tonbo Biosciences tests all antibodies by flow cytometry. Citations are provided as a resource for additional applications that have not been validated by Tonbo Biosciences. Please choose the appropriate format for each application and consult the Materials and Methods section for additional details about the use of any product in these publications.